Medicare, Medicaid to try coverage of GLP-1s for obesity, report says

The Trump administration is reportedly exploring a five-year experimental program for Medicare and Medicaid to cover GLP-1 drugs for obesity, potentially commencing April 2026 for Medicaid and January 2027 for Medicare. This initiative, following a prior rejection of a $40 billion Biden-era proposal, signals a significant policy shift and potential market expansion for high-cost GLP-1s, despite insurer resistance and the drugs' cost exceeding $1,000 per user per month. Such a move would substantially increase pharmaceutical sales and impact federal healthcare spending.

Analysis

A potential Trump administration is reportedly considering a five-year experimental program to facilitate Medicare and Medicaid coverage for GLP-1 drugs for obesity, a significant policy shift from the previously rejected $40 billion Biden administration proposal. This new plan, being developed by the Center for Medicare and Medicaid Innovation, would allow Medicare drug plans and state Medicaid programs to opt-in for coverage of drugs like Ozempic, Wegovy, Mounjaro, and Zepbound, with potential start dates of April 2026 for Medicaid and January 2027 for Medicare. While this represents a substantial expansion of the addressable market beyond existing coverage for diabetes and heart disease, the high cost of these therapies, often exceeding $1,000 per user per month, remains a critical obstacle that has drawn resistance from insurers. The cautious tone from CMS and the evolving stance of HHS Secretary nominee Robert F. Kennedy Jr. underscore the preliminary and politically contingent nature of the proposal, highlighting that any implementation is subject to significant regulatory, fiscal, and political hurdles.

Key Decisions for Investors

• Investors should recognize the potential for expanded Medicare and Medicaid coverage as a significant long-term catalyst for GLP-1 drug manufacturers, but discount its impact in the near-term given the proposed 2026-2027 start date and its contingency on the U.S. election outcome.
• Monitor future announcements from the Center for Medicare and Medicaid Innovation, as the final design of the pilot program and the opt-in rate by states and private plans will be critical determinants of the actual market size increase.
• The high cost of treatment remains the primary risk factor; therefore, focus on any developments related to cost-benefit negotiations between manufacturers and government agencies, as this will heavily influence the program's feasibility and scale.
• Consider the 'experimental' framing of the proposal, which suggests a cautious, data-driven rollout rather than a broad, immediate mandate, implying a more gradual revenue ramp for the covered drugs if the plan proceeds.